Safety of intravenous methamphetamine administration during treatment with bupropion

Thomas F. Newton, John D Roache, Richard De La Garza, Tim Fong, Christopher L. Wallace, Shou Hua Li, Ahmed Elkashef, Nora Chiang, Roberta Kahn

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Rationale: Methamphetamine dependence is a growing problem for which no medication treatments have proven effective. Objectives: We evaluated bupropion, an antidepressant with beneficial effects for the treatment of nicotine dependence, in patients with methamphetamine dependence, to assess the safety and tolerability of methamphetamine administration during bupropion treatment. Methods: Twenty-six participants entered the study and 20 completed the protocol. Participants received intravenous methamphetamine (0, 15, and 30 mg) before and after randomization to twice-daily bupropion (150 mg SR) or matched placebo. Dependent measures included cardiovascular effects of methamphetamine, methamphetamine and amphetamine pharmacokinetics, and peak and trough plasma concentrations of bupropion and its metabolites. Results: Bupropion treatment was well tolerated, with bupropion- and placebo-treated groups reporting similar rates of adverse events. Methamphetamine administration was associated with expected stimulant cardiovascular effects, and these were not accentuated by bupropion treatment. Instead, there was a trend for bupropion to reduce methamphetamine-associated increases in blood pressure and a statistically significant reduction in methamphetamine-associated increases in heart rate. Pharmacokinetic analysis revealed that bupropion treatment reduced the plasma clearance of methamphetamine and also reduced the appearance of amphetamine in the plasma. Methamphetamine administration did not alter the peak and trough plasma concentrations of bupropion or its metabolites. Conclusions: Methamphetamine administration was well tolerated during bupropion treatment. There was no evidence of additive cardiovascular effects when the drugs were coadministered. This study provides initial evidence for the safety of prescribing bupropion for the treatment of methamphetamine abuse and dependence. The impact of bupropion treatment in patients who abuse larger doses of methamphetamine remains undetermined.

Original languageEnglish (US)
Pages (from-to)426-435
Number of pages10
JournalPsychopharmacology
Volume182
Issue number3
DOIs
StatePublished - Nov 2005

Fingerprint

Bupropion
Methamphetamine
Intravenous Administration
Safety
Therapeutics
Amphetamine
Pharmacokinetics
Placebos
Tobacco Use Disorder
Random Allocation
Antidepressive Agents

Keywords

  • Bupropion
  • Drug abuse
  • Methamphetamine
  • Pharmacokinetics
  • Safety evaluation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Newton, T. F., Roache, J. D., De La Garza, R., Fong, T., Wallace, C. L., Li, S. H., ... Kahn, R. (2005). Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology, 182(3), 426-435. https://doi.org/10.1007/s00213-005-0102-8

Safety of intravenous methamphetamine administration during treatment with bupropion. / Newton, Thomas F.; Roache, John D; De La Garza, Richard; Fong, Tim; Wallace, Christopher L.; Li, Shou Hua; Elkashef, Ahmed; Chiang, Nora; Kahn, Roberta.

In: Psychopharmacology, Vol. 182, No. 3, 11.2005, p. 426-435.

Research output: Contribution to journalArticle

Newton, TF, Roache, JD, De La Garza, R, Fong, T, Wallace, CL, Li, SH, Elkashef, A, Chiang, N & Kahn, R 2005, 'Safety of intravenous methamphetamine administration during treatment with bupropion', Psychopharmacology, vol. 182, no. 3, pp. 426-435. https://doi.org/10.1007/s00213-005-0102-8
Newton, Thomas F. ; Roache, John D ; De La Garza, Richard ; Fong, Tim ; Wallace, Christopher L. ; Li, Shou Hua ; Elkashef, Ahmed ; Chiang, Nora ; Kahn, Roberta. / Safety of intravenous methamphetamine administration during treatment with bupropion. In: Psychopharmacology. 2005 ; Vol. 182, No. 3. pp. 426-435.
@article{582e2c7387804aada0453e5d46a9aee9,
title = "Safety of intravenous methamphetamine administration during treatment with bupropion",
abstract = "Rationale: Methamphetamine dependence is a growing problem for which no medication treatments have proven effective. Objectives: We evaluated bupropion, an antidepressant with beneficial effects for the treatment of nicotine dependence, in patients with methamphetamine dependence, to assess the safety and tolerability of methamphetamine administration during bupropion treatment. Methods: Twenty-six participants entered the study and 20 completed the protocol. Participants received intravenous methamphetamine (0, 15, and 30 mg) before and after randomization to twice-daily bupropion (150 mg SR) or matched placebo. Dependent measures included cardiovascular effects of methamphetamine, methamphetamine and amphetamine pharmacokinetics, and peak and trough plasma concentrations of bupropion and its metabolites. Results: Bupropion treatment was well tolerated, with bupropion- and placebo-treated groups reporting similar rates of adverse events. Methamphetamine administration was associated with expected stimulant cardiovascular effects, and these were not accentuated by bupropion treatment. Instead, there was a trend for bupropion to reduce methamphetamine-associated increases in blood pressure and a statistically significant reduction in methamphetamine-associated increases in heart rate. Pharmacokinetic analysis revealed that bupropion treatment reduced the plasma clearance of methamphetamine and also reduced the appearance of amphetamine in the plasma. Methamphetamine administration did not alter the peak and trough plasma concentrations of bupropion or its metabolites. Conclusions: Methamphetamine administration was well tolerated during bupropion treatment. There was no evidence of additive cardiovascular effects when the drugs were coadministered. This study provides initial evidence for the safety of prescribing bupropion for the treatment of methamphetamine abuse and dependence. The impact of bupropion treatment in patients who abuse larger doses of methamphetamine remains undetermined.",
keywords = "Bupropion, Drug abuse, Methamphetamine, Pharmacokinetics, Safety evaluation",
author = "Newton, {Thomas F.} and Roache, {John D} and {De La Garza}, Richard and Tim Fong and Wallace, {Christopher L.} and Li, {Shou Hua} and Ahmed Elkashef and Nora Chiang and Roberta Kahn",
year = "2005",
month = "11",
doi = "10.1007/s00213-005-0102-8",
language = "English (US)",
volume = "182",
pages = "426--435",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Safety of intravenous methamphetamine administration during treatment with bupropion

AU - Newton, Thomas F.

AU - Roache, John D

AU - De La Garza, Richard

AU - Fong, Tim

AU - Wallace, Christopher L.

AU - Li, Shou Hua

AU - Elkashef, Ahmed

AU - Chiang, Nora

AU - Kahn, Roberta

PY - 2005/11

Y1 - 2005/11

N2 - Rationale: Methamphetamine dependence is a growing problem for which no medication treatments have proven effective. Objectives: We evaluated bupropion, an antidepressant with beneficial effects for the treatment of nicotine dependence, in patients with methamphetamine dependence, to assess the safety and tolerability of methamphetamine administration during bupropion treatment. Methods: Twenty-six participants entered the study and 20 completed the protocol. Participants received intravenous methamphetamine (0, 15, and 30 mg) before and after randomization to twice-daily bupropion (150 mg SR) or matched placebo. Dependent measures included cardiovascular effects of methamphetamine, methamphetamine and amphetamine pharmacokinetics, and peak and trough plasma concentrations of bupropion and its metabolites. Results: Bupropion treatment was well tolerated, with bupropion- and placebo-treated groups reporting similar rates of adverse events. Methamphetamine administration was associated with expected stimulant cardiovascular effects, and these were not accentuated by bupropion treatment. Instead, there was a trend for bupropion to reduce methamphetamine-associated increases in blood pressure and a statistically significant reduction in methamphetamine-associated increases in heart rate. Pharmacokinetic analysis revealed that bupropion treatment reduced the plasma clearance of methamphetamine and also reduced the appearance of amphetamine in the plasma. Methamphetamine administration did not alter the peak and trough plasma concentrations of bupropion or its metabolites. Conclusions: Methamphetamine administration was well tolerated during bupropion treatment. There was no evidence of additive cardiovascular effects when the drugs were coadministered. This study provides initial evidence for the safety of prescribing bupropion for the treatment of methamphetamine abuse and dependence. The impact of bupropion treatment in patients who abuse larger doses of methamphetamine remains undetermined.

AB - Rationale: Methamphetamine dependence is a growing problem for which no medication treatments have proven effective. Objectives: We evaluated bupropion, an antidepressant with beneficial effects for the treatment of nicotine dependence, in patients with methamphetamine dependence, to assess the safety and tolerability of methamphetamine administration during bupropion treatment. Methods: Twenty-six participants entered the study and 20 completed the protocol. Participants received intravenous methamphetamine (0, 15, and 30 mg) before and after randomization to twice-daily bupropion (150 mg SR) or matched placebo. Dependent measures included cardiovascular effects of methamphetamine, methamphetamine and amphetamine pharmacokinetics, and peak and trough plasma concentrations of bupropion and its metabolites. Results: Bupropion treatment was well tolerated, with bupropion- and placebo-treated groups reporting similar rates of adverse events. Methamphetamine administration was associated with expected stimulant cardiovascular effects, and these were not accentuated by bupropion treatment. Instead, there was a trend for bupropion to reduce methamphetamine-associated increases in blood pressure and a statistically significant reduction in methamphetamine-associated increases in heart rate. Pharmacokinetic analysis revealed that bupropion treatment reduced the plasma clearance of methamphetamine and also reduced the appearance of amphetamine in the plasma. Methamphetamine administration did not alter the peak and trough plasma concentrations of bupropion or its metabolites. Conclusions: Methamphetamine administration was well tolerated during bupropion treatment. There was no evidence of additive cardiovascular effects when the drugs were coadministered. This study provides initial evidence for the safety of prescribing bupropion for the treatment of methamphetamine abuse and dependence. The impact of bupropion treatment in patients who abuse larger doses of methamphetamine remains undetermined.

KW - Bupropion

KW - Drug abuse

KW - Methamphetamine

KW - Pharmacokinetics

KW - Safety evaluation

UR - http://www.scopus.com/inward/record.url?scp=26844523262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26844523262&partnerID=8YFLogxK

U2 - 10.1007/s00213-005-0102-8

DO - 10.1007/s00213-005-0102-8

M3 - Article

C2 - 16163531

AN - SCOPUS:26844523262

VL - 182

SP - 426

EP - 435

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -